Validation and Verification of Analytical Testing Methods Used for Tobacco Products; Guidance for Industry; Availability
Published Date: 1/7/2025
Notice
Summary
The FDA just released final guidance to help tobacco companies make sure their testing methods for ingredients and product stability are accurate and reliable. This means better, more consistent data when companies submit info about their tobacco products. If you’re in the tobacco biz, get ready to follow these updated testing rules starting now—no extra fees, just clearer standards!
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Final Guidance on Lab Test Methods
On January 7, 2025, FDA issued final guidance titled "Validation and Verification of Analytical Testing Methods Used for Tobacco Products" to help tobacco product manufacturers and testing labs produce more consistent and reliable analytical data for regulatory submissions such as SE reports, PMTAs, and MRTPAs. The guidance finalizes the December 22, 2021 draft and explains recommended validation and verification practices for ingredients, constituents, additives, stability testing, and HPHC reporting.
Guidance Covers Synthetic Nicotine Products
The final guidance updates the Background section to reflect that the statutory term "tobacco product" now includes non-tobacco (synthetic) nicotine as a result of Pub. L. 117-103. That means the guidance's validation and verification recommendations apply to products containing synthetic nicotine as well as traditional tobacco products.
Lab Accreditation Documentation Updated
The final guidance includes updates reflecting PMTA and SE Report rule requirements for documenting laboratory accreditation. Applicants submitting PMTAs or SE reports should follow the updated recommendations for how to document laboratory accreditation in support of analytical testing data.
New Flexibility in Validation Approaches
FDA's final guidance acknowledges that alternative validation procedures may differ from the guidance and adds technical options such as a spike-and-recovery approach to determine limit of detection and an equation to adjust for interference bias when determining selectivity. The guidance also clarifies the Agency's view on using linear regression (R2) for linearity.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in